Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00VAJ
|
|||
| Former ID |
DNC003918
|
|||
| Drug Name |
ORBOFIBAN
|
|||
| Synonyms |
Orbofiban; UNII-FGJ53JS7PT; 163250-90-6; FGJ53JS7PT; CHEMBL64706; SC-57099B; Orbofiban [INN]; AC1L435J; SCHEMBL7854981; DTXSID20167543; ZINC3951736; BDBM50092109; AKOS022181223; AJ-47472; ethyl 3-[[(3S)-1-(4-carbamimidoylphenyl)-2-oxopyrrolidin-3-yl]carbamoylamino]propanoate; 3-{(S)-3-[1-(4-Carbamimidoyl-phenyl)-2-oxo-pyrrolidin-3-yl]-ureido}-propionic acid ethyl ester; beta-Alanine, N-((((3S)-1-(4-(aminoiminomethyl)phenyl)-2-oxo-3- pyrrolidinyl)amino)carbonyl)-, ethyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Angina pectoris [ICD-11: BA40; ICD-9: 413] | Discontinued in Phase 3 | [1] | |
| Cardiovascular disease [ICD-11: BA00-BE2Z] | Discontinued in Phase 3 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H23N5O4
|
|||
| Canonical SMILES |
CCOC(=O)CCNC(=O)NC1CCN(C1=O)C2=CC=C(C=C2)C(=N)N
|
|||
| InChI |
1S/C17H23N5O4/c1-2-26-14(23)7-9-20-17(25)21-13-8-10-22(16(13)24)12-5-3-11(4-6-12)15(18)19/h3-6,13H,2,7-10H2,1H3,(H3,18,19)(H2,20,21,25)/t13-/m0/s1
|
|||
| InChIKey |
VJDOPFARMOLELX-ZDUSSCGKSA-N
|
|||
| CAS Number |
CAS 163250-90-6
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007819) | |||
| REF 2 | Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50. | |||
| REF 3 | Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev. 2001 May;21(3):211-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.